世界の静脈疾患治療市場2022年ー2031年:治療種類別(手術、治療)、製品別

◆英語タイトル:Venous Diseases Treatment Market (Treatment Type: Surgeries and Therapies; and Product: Ablation Devices, Venous Stents, Venous Closure Products, Sclerotherapy Injection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031

Transparency Market Researchが発行した調査報告書(TMR22OT098)◆商品コード:TMR22OT098
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2022年7月19日
◆ページ数:150
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,795 ⇒換算¥857,660見積依頼/購入/質問フォーム
Multi User(5名様閲覧)USD8,795 ⇒換算¥1,301,660見積依頼/購入/質問フォーム
Corporate License(法人閲覧)USD11,795 ⇒換算¥1,745,660見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の本調査レポートでは、世界の静脈疾患治療市場規模について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療種類別(深部静脈血栓性静脈炎、下肢静脈瘤、表在性血栓性静脈炎、慢性静脈不全、静脈性潰瘍)分析、製品別(アブレーション装置、静脈ステント、静脈閉鎖治療、硬化療法注射、その他)分析、エンドユーザー別(病院、クリニック、外科手術センター)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)分析、競争状況など、以下の項目を掲載しております。本書では、Medtronic、AngioDynamics、Alma Lasers、Biolitec AG Untere Viaduktgasse、Becton Dickinson and Company、Boston Scientific Corporation、Abbott Laboratories、B.Braun Melsungen Ag、Teleflex Incorporated、Lumenis、Philipsなどの企業情報が含まれています。

・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト

・世界の静脈疾患治療市場規模:治療種類別
- 深部静脈血栓性静脈炎治療の市場規模
- 下肢静脈瘤治療の市場規模
- 表在性血栓性静脈炎治療の市場規模
- 慢性静脈不全治療の市場規模
- 静脈性潰瘍治療の市場規模

・世界の静脈疾患治療市場規模:製品別
- 静脈疾患用アブレーション装置の市場規模
- 静脈疾患用静脈ステントの市場規模
- 静脈疾患用静脈閉鎖治療の市場規模
- 静脈疾患用硬化療法注射の市場規模
- その他製品の市場規模

・世界の静脈疾患治療市場規模:エンドユーザー別
- 病院における市場規模
- クリニックにおける市場規模
- 外科手術センターにおける市場規模

・世界の静脈疾患治療市場規模:地域別
- 北米の静脈疾患治療市場規模
- ヨーロッパの静脈疾患治療市場規模
- アジア太平洋の静脈疾患治療市場規模
- 中南米の静脈疾患治療市場規模
- 中東/アフリカの静脈疾患治療市場規模

・競争状況

Venous Diseases Treatment Market – Scope of Report
TMR’s report on the global venous diseases treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global venous diseases treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global venous diseases treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the venous diseases treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global venous diseases treatment market.
venous diseases treatment report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global venous diseases treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global venous diseases treatment market.

The report delves into the competitive landscape of the global venous diseases treatment market. Key players operating in the global venous diseases treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global venous diseases treatment market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market venous diseases treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Venous Diseases Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Porter’s Five Force Analysis
5. Key Insights
5.1. Regulatory Scenario by Region/globally
5.2. Technological Advancements
5.3. Pipeline Analysis
5.4. Key Mergers & Acquisitions
5.5. Disease Prevalence & Incidence Rate globally with key countries
5.6. Reimbursement Scenario by Region/globally
6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Surgeries
6.3.1.1. Angioplasty or Stenting
6.3.1.2. Vein Ligation and Stripping
6.3.1.3. Vena Cava Filter
6.3.1.4. Ambulatory Phlebectomy
6.3.1.5. Others
6.3.2. Therapies
6.3.2.1. Sclerotherapy
6.3.2.2. Radiofrequency Ablation Therapy
6.3.2.3. Laser Treatment
6.4. Market Attractiveness Analysis, by Treatment
7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017–2031
7.3.1. Deep-vein Thrombophlebitis
7.3.2. Varicose Veins
7.3.3. Superficial Thrombophlebitis
7.3.4. Chronic Venous Insufficiency
7.3.5. Venous Ulcers
7.3.6. Others
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Product Type, 2017–2031
8.3.1. Ablation Devices
8.3.2. Venous Stents
8.3.3. Venous Closure Treatments
8.3.4. Sclerotherapy Injection
8.3.5. Others
8.4. Market Attractiveness Analysis, by Product Type
9. Global Venous Diseases Treatment Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Ambulatory centers
9.4. Market Attractiveness Analysis, by End-user
10. Global Venous Diseases Treatment Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Venous Diseases Treatment Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Surgeries
11.2.1.1. Angioplasty or Stenting
11.2.1.2. Vein Ligation and Stripping
11.2.1.3. Vena Cava Filter
11.2.1.4. Ambulatory Phlebectomy
11.2.1.5. Others
11.2.2. Therapies
11.2.2.1. Sclerotherapy
11.2.2.2. Radiofrequency Ablation Therapy
11.2.2.3. Laser Treatment
11.3. Market Value Forecast, by Disease Type, 2017–2031
11.3.1. Deep-vein Thrombophlebitis
11.3.2. Varicose Veins
11.3.3. Superficial Thrombophlebitis
11.3.4. Chronic Venous Insufficiency
11.3.5. Venous Ulcers
11.3.6. Others
11.4. Market Value Forecast, by Product Type, 2017–2031
11.4.1. Ablation Devices
11.4.2. Venous Stents
11.4.3. Venous Closure Treatments
11.4.4. Sclerotherapy Injection
11.4.5. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Ambulatory centers
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Disease Type
11.7.3. By Product Type
11.7.4. By End-user
11.7.5. By Country/Sub-region
12. Europe Venous Diseases Treatment Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Surgeries
12.2.1.1. Angioplasty or Stenting
12.2.1.2. Vein Ligation and Stripping
12.2.1.3. VeEnd Use Cava Filter
12.2.1.4. Ambulatory Phlebectomy
12.2.1.5. Others
12.2.2. Therapies
12.2.2.1. Sclerotherapy
12.2.2.2. Radiofrequency Ablation Therapy
12.2.2.3. Laser Treatment
12.3. Market Value Forecast, by Disease Type, 2017–2031
12.3.1. Deep-vein Thrombophlebitis
12.3.2. Varicose Veins
12.3.3. Superficial Thrombophlebitis
12.3.4. Chronic Venous Insufficiency
12.3.5. Venous Ulcers
12.3.6. Others
12.4. Market Value Forecast, by Product Type, 2017–2031
12.4.1. Ablation Devices
12.4.2. Venous Stents
12.4.3. Venous Closure Treatments
12.4.4. Sclerotherapy Injection
12.4.5. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Ambulatory centers
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.7. Market Attractiveness Analysis
12.7.1. By Treatment
12.7.2. By Disease Type
12.7.3. By Product Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Venous Diseases Treatment Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Surgeries
13.2.1.1. Angioplasty or Stenting
13.2.1.2. Vein Ligation and Stripping
13.2.1.3. VeEnd Use Cava Filter
13.2.1.4. Ambulatory Phlebectomy
13.2.1.5. Others
13.2.2. Therapies
13.2.2.1. Sclerotherapy
13.2.2.2. Radiofrequency Ablation Therapy
13.2.2.3. Laser Treatment
13.3. Market Value Forecast, by Disease Type, 2017–2031
13.3.1. Deep-vein Thrombophlebitis
13.3.2. Varicose Veins
13.3.3. Superficial Thrombophlebitis
13.3.4. Chronic Venous Insufficiency
13.3.5. Venous Ulcers
13.3.6. Others
13.4. Market Value Forecast, by Product Type, 2017–2031
13.4.1. Ablation Devices
13.4.2. Venous Stents
13.4.3. Venous Closure Treatments
13.4.4. Sclerotherapy Injection
13.4.5. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Ambulatory centers
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Treatment
13.7.2. By Disease Type
13.7.3. By Product Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Venous Diseases Treatment Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Surgeries
14.2.1.1. Angioplasty or Stenting
14.2.1.2. Vein Ligation and Stripping
14.2.1.3. VeEnd Use Cava Filter
14.2.1.4. Ambulatory Phlebectomy
14.2.1.5. Others
14.2.2. Therapies
14.2.2.1. Sclerotherapy
14.2.2.2. Radiofrequency Ablation Therapy
14.2.2.3. Laser Treatment
14.3. Market Value Forecast, by Disease Type, 2017–2031
14.3.1. Deep-vein Thrombophlebitis
14.3.2. Varicose Veins
14.3.3. Superficial Thrombophlebitis
14.3.4. Chronic Venous Insufficiency
14.3.5. Venous Ulcers
14.3.6. Others
14.4. Market Value Forecast, by Product Type, 2017–2031
14.4.1. Ablation Devices
14.4.2. Venous Stents
14.4.3. Venous Closure Treatments
14.4.4. Sclerotherapy Injection
14.4.5. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Ambulatory centers
14.6. Market Value Forecast, by Country/Sub-region, 2017 – 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Treatment
14.7.2. By Disease Type
14.7.3. By Product Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment, 2017–2031
15.2.1. Surgeries
15.2.1.1. Angioplasty or Stenting
15.2.1.2. Vein Ligation and Stripping
15.2.1.3. VeEnd Use Cava Filter
15.2.1.4. Ambulatory Phlebectomy
15.2.1.5. Others
15.2.2. Therapies
15.2.2.1. Sclerotherapy
15.2.2.2. Radiofrequency Ablation Therapy
15.2.2.3. Laser Treatment
15.3. Market Value Forecast, by Disease Type, 2017–2031
15.3.1. Deep-vein Thrombophlebitis
15.3.2. Varicose Veins
15.3.3. Superficial Thrombophlebitis
15.3.4. Chronic Venous Insufficiency
15.3.5. Venous Ulcers
15.3.6. Others
15.4. Market Value Forecast, by Product Type, 2017–2031
15.4.1. Ablation Devices
15.4.2. Venous Stents
15.4.3. Venous Closure Treatments
15.4.4. Sclerotherapy Injection
15.4.5. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Ambulatory centers
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
16. Competitive Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Zimmer Biomet Holdings, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. Medtronic
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. AngioDynamics
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Alma Lasers
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Biolitec AG Untere Viaduktgasse
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Becton, Dickinson and Company
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Boston Scientific Corporation
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Abbott Laboratories
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. B. Braun Melsungen AG
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Teleflex Incorporated
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Lumenis
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Company Financials
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
16.3.12. Philips
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Company Financials
16.3.12.3. Growth Strategies
16.3.12.4. SWOT Analysis



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の静脈疾患治療市場2022年ー2031年:治療種類別(手術、治療)、製品別(Venous Diseases Treatment Market (Treatment Type: Surgeries and Therapies; and Product: Ablation Devices, Venous Stents, Venous Closure Products, Sclerotherapy Injection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆